Milla Pharmaceuticals, Inc
Form 483 issued March 12, 2026 · White Bear Lake, Minnesota
- Inspection
- Mar 9 – Mar 12, 2026
- Investigator
- Sharon L. Matson
- Observations
- 1
- Pages
- 2
- FEI number
- 3015401429
In short: On March 12, 2026, FDA issued a Form 483 with 1 observation to Milla Pharmaceuticals, Inc in White Bear Lake, Minnesota (FEI 3015401429) after an inspection that ran Mar 9 – Mar 12, 2026. The investigator was Sharon L. Matson. The most-cited regulation is 21 CFR 314.80 (postmarketing reporting of adverse drug experiences).
What FDA observed
Preview: the opening words of each observation- 01
Written procedures have not been developed for the of post…
This inspection in context
Sharon L. Matson
3 documents · 2018–2026
Cites 312.62(a) (investigator recordkeeping and record retention) more than any other section. Most of their documents are for sites in Minnesota.
The firmMilla Pharmaceuticals, Inc history
The site's inspection history, in date order.
Similar 483sOther sites cited under 314.80(b)
See how FDA wrote the same problem up elsewhere.
Questions about this 483
What did FDA find at Milla Pharmaceuticals, Inc?
FDA listed 1 observation on this Form 483. The most-cited regulation is 21 CFR 314.80 (postmarketing reporting of adverse drug experiences). The opening words of each observation are shown on this page.
Who inspected Milla Pharmaceuticals, Inc?
Sharon L. Matson is named on this Form 483, for the inspection of Mar 9 – Mar 12, 2026. Each investigator has a profile showing what they cite most.
When was Milla Pharmaceuticals, Inc inspected by FDA?
The inspection ran Mar 9 – Mar 12, 2026, and the Form 483 is dated March 12, 2026.
How do I get the full Form 483 for Milla Pharmaceuticals, Inc?
Download the original PDF from FDA Intel for $99, with no subscription. Your first Form 483 or letter is on us. You also get an invoice PDF with the order.